Verrica Pharmaceuticals Inc (VRCA)
7.29
+0.07
(+0.97%)
USD |
NASDAQ |
Jun 28, 16:00
7.27
-0.02
(-0.27%)
After-Hours: 20:00
Verrica Pharmaceuticals Research and Development Expense (Annual): 20.30M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 20.30M |
| December 31, 2022 | 12.20M |
| December 31, 2021 | 15.93M |
| December 31, 2020 | 15.67M |
| Date | Value |
|---|---|
| December 31, 2019 | 15.44M |
| December 31, 2018 | 12.83M |
| December 31, 2017 | 3.73M |
| December 31, 2016 | 1.709M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
12.20M
Minimum
2022
20.30M
Maximum
2023
15.91M
Average
15.67M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Emergent BioSolutions Inc | 111.40M |
| Macrogenics Inc | 166.58M |
| Aquestive Therapeutics Inc | 13.10M |
| Recursion Pharmaceuticals Inc | 241.23M |
| Omega Therapeutics Inc | 77.17M |